Phone-A-Friend
Team at the Center
Coordinating Care for Patients with Intermediate-Stage HCC
Suggested Readings
TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC).
Dong J, et al. Ann Oncol. 2025;36(suppl 1):S62.
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.
Karin M and Kim JY. Mol Oncol. 2025;19(2):275-294.
Current treatment methods in hepatocellular carcinoma.
Krupa K, et al. Cancers (Basel). 2024;16(23):4059.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Kudo M, et al. Lancet. 2025;405(10474):203-215.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, et al. Lancet. 2025;405(10474):216-232.
Linked Resources
Clinical Practice Guidelines
NCCN Guidelines®: Hepatocellular Carcinoma, version 1.2025
Benson AB, et al. J Natl Compr Canc Netw. 2025.
American Association for the Study of Liver Diseases (AASLD).
Clinician and Patient Resources
American Cancer Society
American Liver Foundation
Global Liver Institute
Related activities
Webcast Series
0.25 CME/CE
Management of newly diagnosed patient with intermediate-stage HCC
Module 1
| Faculty: | Zachary T. Berman, MD ; Richard S. Finn, MD |
| Release: | 09/26/2025 |
| Expiration: | 09/26/2026 |
